Financial Data and Key Metrics Changes - As of December 31, 2025, Cellectis reported cash equivalents, restricted cash, and fixed-term deposits amounting to $211 million, a decrease of $53 million from $264 million as of December 31, 2024, primarily due to cash payments and operational expenses [19][20] - The company managed its cash with discipline, focusing on the development of lasme-cel and eti-cel, and believes its current cash position is sufficient to fund operations into the second half of 2027 [18][19] Business Line Data and Key Metrics Changes - Lasme-cel achieved a 100% overall response rate in the target phase 2 population, with 80% of patients achieving minimal residual disease (MRD) negative status [5][12] - Eti-cel demonstrated an 88% overall response rate and a 63% complete response rate in heavily pre-treated patients during phase 1 trials [8][16] Market Data and Key Metrics Changes - Cellectis is advancing its pivotal phase 2 trial for lasme-cel, with site openings in North America and Europe expected to continue into 2026 [7][12] - The company is also investigating eti-cel's potential impact with low-dose interleukin-2 support to enhance CAR-T efficacy without increasing toxicity [8][16] Company Strategy and Development Direction - Cellectis aims to transform into a late-stage development organization, with 2026 expected to be a year of significant milestones and data readouts [10][17] - The company is focused on delivering clinical results for patients with no therapeutic solutions, emphasizing the importance of its allogeneic CAR-T approach [4][5] Management's Comments on Operating Environment and Future Outlook - Management highlighted the challenges faced by biotechnology companies in recent years but emphasized Cellectis's commitment to advancing its clinical programs [4][5] - The management expressed confidence in the potential of lasme-cel and eti-cel to provide significant therapeutic options for patients with difficult-to-treat cancers [6][8] Other Important Information - Cellectis's gene editing platform is becoming the backbone of a broader allogeneic CAR-T ecosystem, with partnerships with Servier and Iovance advancing their respective programs [9][10] - The company anticipates presenting full phase 1 data for eti-cel later this year and expects to submit a Biologics License Application (BLA) for lasme-cel in the second half of 2028 [17][19] Q&A Session Summary Question: Update on lasme-cel and BALLI-01 enrollment - Management confirmed that recruitment is on track and expects to complete data analysis by the end of the year for the first 40 patients [23][24] Question: Expectations for dose optimization in the pivotal study - Management indicated that they have a strong analysis plan to differentiate between the two alemtuzumab dose levels, focusing on efficacy and safety [25][26] Question: Details on Servier arbitration and its impact - Management clarified that the arbitration ruling allows Cellectis to develop UCART19 independently while remaining eligible for milestones related to cema-cel [28][30] Question: Safety of CD52 preconditioning - Management emphasized the importance of alemtuzumab in optimizing lymphodepletion and achieving better outcomes [32][33] Question: Update on esiCell and patient follow-up - Management provided a top-line update on esiCell, indicating strong complete remission rates and plans for further data on IL-2 cohorts [35][36] Question: Competitive landscape regarding CD19 therapies - Management noted that their focus is on CD22, differentiating their product from others targeting CD19, and emphasized the need for alternative therapies for patients [41][42] Question: Expectations for EHA updates - Management indicated that they will present an updated dataset at EHA, including additional patients and insights on optimal lymphodepletion [50][52] Question: Outpatient setting for lymphodepletion procedures - Management stated that regulatory requirements currently necessitate inpatient delivery, but there is potential for outpatient use in the future [56][57] Question: AstraZeneca partnership updates - Management expressed satisfaction with the collaboration and indicated that updates will be provided when appropriate [58][60]

Management transitioned the company from a technology developer to a commercially driven 'gene editing engine' integrated into customer breeding programs. The value proposition has shifted to 'time-bound, predictable' trait development, returning edited elite germplasm to customers within 12 to 15 months. Performance in the rice (RISE) program is driven by seven customers representing a potential $200 million annual royalty opportunity across the Americas. The commercial model is evolving beyond sin ...

Management repeatedly pointed to rice as the company’s clearest near-term royalty opportunity. Beetham said Cibus has seven rice customers across the U.S. and Latin America representing “over $200 million in potential annual royalty opportunity” tied to herbicide-tolerant traits. The company said it remains on track for initial market entry in Latin America in 2027, potential U.S. expansion in 2028, and entry into India and Asia “closer to 2030.”Beetham said Cibus can now take a customer’s elite genetics, m ...

Core Insights - Precision BioSciences Inc. reported adjusted earnings of $0.36 per share, significantly surpassing the Zacks Consensus Estimate of a -$0.21 loss per share, marking an earnings surprise of +271.43% and a notable improvement from the adjusted loss of $3.2 per share in the same quarter last year [1][2] - The company's revenue for the quarter ended December 31, 2025, was $34.2 million, exceeding the Zacks Consensus Estimate by 178.08%, and reflecting a dramatic increase from $0.6 million in the prior-year quarter, primarily driven by collaboration-related payments [2][3] - Precision BioSciences operates in the Zacks Medical - Biomedical and Genetics industry and announced its Q4 and fiscal year 2025 financial results on March 12, 2026 [3] Market Performance - On March 13, 2026, Jefferies set a price target of $19 for DTIL, lowered from a prior $21, while maintaining a positive outlook, indicating a potential upside of approximately 235% from the stock's trading price of $5.67 [4] - The company's market capitalization is approximately $130 million, with a trading volume of 277,693 shares on March 13, 2026, and the stock has ranged from a low of $3.53 to a high of $8.82 over the past year [5] Clinical Developments - Precision BioSciences has made significant clinical progress with its PBGENE-HBV program for chronic hepatitis B, presenting late-breaking Phase 1 data from the ELIMINATE-B trial, demonstrating safety, tolerability, and antiviral activity [6] - The CEO highlighted these advancements as positioning the company for continued success in 2026 and beyond, supported by an extended cash runway through 2028 following the strong quarterly results [7]

Core Insights - Precision BioSciences has received two Notices of Allowance from the U.S. Patent and Trademark Office for its PBGENE-HBV program, which focuses on gene editing therapies for Hepatitis B [1] - The first patent application covers engineered meganucleases targeting the Hepatitis B virus genome, while the second application pertains to polypeptide linkers used in these engineered nucleases [1] - The patents, once granted, are expected to provide composition-of-matter protection for the PBGENE-HBV ARCUS nuclease until at least November 2044, enhancing the company's intellectual property portfolio [1] Company Overview - Precision BioSciences is a clinical stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs [1] - The PBGENE-HBV program is currently in a global first-in-human clinical trial aimed at providing a potentially curative treatment for chronic Hepatitis B infection [1] - The program has received Fast Track designation from the FDA, indicating its potential significance in addressing chronic Hepatitis B [1] Patent Details - The first Notice of Allowance relates to U.S. Patent Application No. 19/347,136, which includes claims for the ARCUS nuclease used in PBGENE-HBV [1] - The second Notice of Allowance pertains to U.S. Patent Application No. 19/273,982, covering any polypeptide that includes a novel, shortened polypeptide linker developed by Precision [1] - Both patents are expected to provide overlapping coverage across multiple patent families, strengthening the company's position in the market [1]

Core Viewpoint - CRISPR Therapeutics AG has announced a private offering of $550 million in convertible senior notes due 2031, which was upsized from a previously announced $350 million offering [1][7] Group 1: Offering Details - The offering is targeted at qualified institutional buyers under Rule 144A of the Securities Act [1] - The notes will have an effective coupon of 1.125%, increased to 1.7308% due to anticipated Swiss tax withholding [2] - Interest payments will be made semiannually starting September 1, 2026, with maturity on March 1, 2031 [2] Group 2: Conversion and Redemption - Holders can convert their notes into common shares at a conversion rate of 13.0617 shares per $1,000 principal amount, equating to an initial conversion price of approximately $76.56 per share [3][4] - The conversion price represents a 45% premium over the last reported sale price of $52.80 per share on March 10, 2026 [4] - The company may redeem the notes starting March 6, 2029, under specific conditions related to the stock price [5] Group 3: Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $536.3 million, or $585.2 million if the option for additional notes is fully exercised [7] - The proceeds will be used for general corporate purposes [7] Group 4: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on gene-based medicines for serious diseases, with a notable achievement being the approval of CASGEVY, the first CRISPR-based therapy [10] - The company is advancing a diversified pipeline across various therapeutic areas and has established strategic collaborations with major biopharmaceutical partners [10]

Core Viewpoint - CRISPR Therapeutics' stock fell over 12% due to the announcement of new debt issuance, which may dilute existing shareholders' stakes [1][4]. Group 1: Fundraising Details - The company plans to sell $350 million in convertible notes for general corporate purposes, with an option for buyers to purchase an additional $52.5 million [2]. - The notes will mature in early 2031 unless redeemed, repurchased, or converted into common stock [2]. Group 2: Financial Context - CRISPR's current market capitalization is $5.0 billion, with $347.6 million in cash and cash equivalents at the end of last year [3]. - The company has total liabilities of $343.4 million, including $149 million in current liabilities, and burned through $345 million last year for drug development [3]. Group 3: Market Reaction and Future Outlook - The market's negative response to the fundraising announcement is not surprising, as it reflects the typical behavior of biotech startups raising capital [4]. - Despite the setback, the situation does not eliminate the bullish argument for potential investors, as it may present a wider window of opportunity [6].

Core Viewpoint - CRISPR Therapeutics AG plans to offer $350 million in convertible senior notes due 2031, with an option for an additional $52.5 million, to qualified institutional buyers, subject to market conditions [1][2] Group 1: Offering Details - The notes will be senior, unsecured obligations of the company, accruing interest payable semiannually starting September 1, 2026, and maturing on March 1, 2031 [2] - Upon conversion, the company will deliver common shares with a nominal value of CHF 0.03 per share, with specific terms to be determined at the pricing of the offering [2] Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes [3] Group 3: Company Overview - CRISPR Therapeutics is a leading biopharmaceutical company focused on developing gene-based medicines for serious diseases, having achieved a milestone with the approval of CASGEVY, the first CRISPR-based therapy for sickle cell disease and beta thalassemia [5] - The company has a diversified pipeline across various therapeutic areas, including hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine, and rare diseases [5] - CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals, and operates R&D facilities in Boston and San Francisco [5]

One biotech company has managed to develop gene-edited stoneless cherries. It is only a matter of time until yet more challenging fruits are similarly eviscerated https://t.co/UVOnUIgxUN ...

Core Viewpoint - Intellia Therapeutics is gaining attention due to its innovative gene editing capabilities and recent positive developments in its clinical trials, making it a potential investment opportunity [1][5]. Company Overview - Intellia Therapeutics is a mid-cap biotech company focused on gene editing and developing treatments for rare diseases [2]. - The company has seen a significant increase in its stock price, with shares up 47% this year [2]. Pipeline Candidates - Intellia's leading candidates include lonvo-z, an investigational treatment for hereditary angioedema, and nex-z, which targets transthyretin amyloidosis [4]. - Nex-z is particularly noteworthy as it offers a one-time treatment option for a condition affecting hundreds of thousands of patients globally [9]. Regulatory Developments - The FDA previously placed clinical holds on nex-z due to a patient death linked to liver failure, but these holds have now been lifted, allowing Intellia to proceed with its studies [5]. - The company is adopting a more cautious approach in its late-stage studies for nex-z, including excluding patients with certain liver issues [8]. Market Data - Intellia Therapeutics has a market capitalization of $1.6 billion, with a current stock price of $13.41 [6][7]. - The stock has experienced a 52-week range of $5.90 to $28.25, indicating significant volatility [7]. Strategic Partnerships - Intellia has a partnership with biotech giant Regeneron to develop nex-z, which may enhance its prospects in the market [9].